Search Results - "Berges, Gloria Damoaliga"

Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso by Sirima, Sodiomon B., Ouedraogo, Alphonse, Barry, Nouhoun, Siribie, Mohamadou, Tiono, Alfred B., Nébié, Issa, Konaté, Amadou T., Berges, Gloria Damoaliga, Diarra, Amidou, Ouedraogo, Moussa, Soulama, Issiaka, Hema, Alimatou, Datta, Shrimati, Liang, Yuanyuan, Rotrosen, Elizabeth T., Tracy, J. Kathleen, Jamka, Leslie P., Neuzil, Kathleen M., Laurens, Matthew B.

“…•This is the first study on the co-administration of typhoid conjugate vaccine (TCV) in West Africa.•Co-administration of TCV with routine vaccines in a…”
Get full text

Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial by Sirima, Sodiomon B., Ouedraogo, Alphonse, Barry, Nouhoun, Siribie, Mohamadou, Tiono, Alfred, Nébié, Issa, Konaté, Amadou, Berges, Gloria Damoaliga, Diarra, Amidou, Ouedraogo, Moussa, Bougouma, Edith C., Soulama, Issiaka, Hema, Alimatou, Datta, Shrimati, Liang, Yuanyuan, Rotrosen, Elizabeth T., Tracy, J. Kathleen, Jamka, Leslie P., Oshinsky, Jennifer J., Pasetti, Marcela F., Neuzil, Kathleen M., Laurens, Matthew B.

“…•This is the first study on the co-administration of typhoid conjugate vaccine (TCV) in West Africa.•Co-administration of TCV with routine vaccines in a…”
Get full text

PA-463 Phase 1b randomized, controlled, double-blinded, age de-escalation trial to evaluate the safety, reactogenicity and immunogenicity of BK-SE36/CpG malaria vaccine in Burkinabe healthy adults and children by Ouedraogo, Alphonse, Bougouma, Edith Christiane, Houard, Sophie, Palacpac, Nirianne MQ, Nebie, Issa, Sawadogo, Jean, Berges, Gloria Damoaliga, Soulama, Issiaka, Diarra, Amidou, Hien, Denise, Kouanda, Seni, D’Alessio, Flavia, Leroy, Odile, Tiono, Alfred B, Horii, Toshihiro, Sirima, Sodiomon B

“…BackgroundBK-SE36/CpG is a recombinant Plasmodium falciparum vaccine candidate targeting blood-stage parasites. The P. falciparum SE36 protein was expressed in…”
Get full text